Home » Topics » BioWorld Science

BioWorld Science
RSS

First phase IIa patients receive BrachySil for liver cancer

June 17, 2004

IR-103 enters first clinical study for HIV

June 17, 2004

Ovation acquires Buronil from Lundbeck

June 17, 2004

Daily Infergen plus ribavirin evaluated for HCV in new DIRECT trial

June 17, 2004

SVT-40776 progresses into phase II for urinary incontinence

June 17, 2004

Symadex enters phase I in patients with advanced solid tumors

June 17, 2004

Pivotal phase III trial of Rencarex for renal cell carcinoma opens enrollment

June 17, 2004

First patient enrolled in phase I/II study of TheraCIM hR3 for pediatric glioma

June 17, 2004

ZYC-101a shows 100% efficacy in patients with high-grade cervical dysplasia

June 17, 2004

Sosei's phase I trial of SOU-001 cleared to begin in U.K.

June 17, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...